ArticleHaematologica2026
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FLT3 inhibition after transplantation: real-world evidence confirms common practice.Haematologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FLT3-mutation occurs in 25-30% of acute myeloid leukemia (AML) and confers high relapse risk and inferior survival. Allogeneic hematopoietic cell transplantation (allo-HCT) offers curative potential, yet relapse remains a major post-transplant challenge. Maintenance therapy with FLT3 inhibitors (FLT3i) after allo-HCT has emerged as a promising strategy, but real- world evidence remains limited. This study aimed to assess the impact of FLT3i maintenance on transplant outcomes. We analyzed 523 adults with FLT3-internal tandem duplications (ITD) AML in first complete remission who underwent allo- HCT between 2011 and 2023 in 13 German transplant centers participating in the national German Registry for Hemato-poietic Stem Cell Transplantation and Cell Therapy registry; 22% received FLT3i maintenance (sorafenib 49%, midostaurin 37%, gilteritinib 5%, unknown 9%). In multivariable analyses, FLT3i maintenance improved overall survival (OS) (hazard ratio [HR]=2.25; 95% confidence interval [CI]: 1.28-3.95; P=0.005), relapse-free survival (RFS) (HR=1.72; 95% CI: 1.05- 2.81; P=0.030), non-relapse mortality (HR=3.62, 95% CI: 1.08-12.11; P=0.037), and graft-versus-host disease-free, relapse-free survival (GRFS) (HR=1.59; 95% CI: 1.06-2.40; P=0.025). The cumulative incidence of relapse did not differ. In univariate analyses (UVA), OS benefits were observed in MRD-positive (HR=2.35; 95% CI: 1.04-5.31; P=0.025) and MRD-negative patients (HR=2.64; 95% CI: 1.05-6.68; P=0.020. Sorafenib maintenance (N=50) demonstrated superior efficacy with 5-year OS of 85% versus 62% (HR=2.979; P=0.0045) and RFS of 84% versus 55% (HR=2.771; P=0.0043) compared to no maintenance. These real-world findings, while limited by the retrospective design and potential selection bias, align with randomized trial data and support the use of FLT3i maintenance as part of post-transplant care for FLT3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.